

Send your news item suggestions to jonnwu@bccancer.bc.ca

Dear friends and ISOO members,

The 2022 MASCC and ISOO Annual General Meeting will be starting in two days. We would like to highlight another set of exciting ISOO Sessions, and will be presenting the 2022 Distinguished Service Award at the Opening Ceremonies. We would also encourage you to attend the Oral Care Study Group Parallel Sessions, and our ISOO Annual General Meeting (Business Meeting) will be held on **Thursday, June 23, from 3:15 to 4:15 pm EST, in Pier 2/3 (Westin Harbour Hotel).**

For more information, you can check out the full schedule here:

<https://mascc.memberclicks.net/2022-program#>

See you soon,
Your ISOO Board

MASCC/ISOO • TORONTO 2022
ANNUAL MEETING • SUPPORTIVE CARE IN CANCER JUNE 23-25

ISOO Session Highlights & More!

Oral Care E-Poster Session

Thursday, June 23, 13:30 - 15:00

Location: E-Poster Stage 2, Metropolitan Centre, CC

ISOO General Assembly, all members welcome

Thursday, June 23 3:15-4:15 PM EDT

Pier 2/3 Westin Harbour Hotel

Innovations in Head and Neck Survivorship

Friday, June 24 8:45 AM – 10:15 AM EDT *Livestream

- Molecular Mechanistic Insights are enabling Safe and Effective Clinical Translation of Photobiomodulation therapy in Supportive Cancer Care - Asst Prof Praveen Arany (USA)
- Immunotherapy and Oral Complications - Prof Alessandro Villa (USA)

Surgical Reconstruction and Prosthetic Rehabilitation for Head and Neck Cancer Patients

Friday, June 24 10:45 AM – 12:15 PM EDT *Livestream

- Virtual Surgical Planning in Maxilla and Mandible Reconstruction - Assoc Prof Eitan Prisman (Canada)
- Complications and Challenges in Free Flap Implantation - Dr David Yang (Canada)

Oral Microbiome in Cancer Patients

Friday, June 24 1:45 PM – 3:15 PM EDT *Livestream

- The Oral Microbiota in Cancer Patients: From Composition to Biomarkers - Dr Julia Bruno (Brazil)
- Oral Microbiome in Head and Neck Cancer Patients - Prof Yvonne Kapila (USA)

Big Data to Predict Mucositis Risk and Severity

Friday, June 24 3:45 PM – 5:15 PM EDT *Livestream

- Leveraging Big Data for Precision Health: Considerations and Perspectives from Epidemiology - Assoc Prof Paul Wesson (USA)
- No Pain, No Gain: Is Mucositis Development Linked to Better Treatment Response? - Dr Barbara Murphy (USA)

Precision Medicine and Cancer Supportive Care: Past, Present and Future Directions

Friday, June 24 3:45 PM – 5:15 PM EDT

- New Ways of Predicting Cancer Treatment Toxicities: Multi-Omics Approaches - Prof Stephen Sonis (USA)
- Genetic Predictors of Chemotherapy Neuropathy: Ready for Prime Time? - Dr Daniel Hertz (USA)

Patient Empowerment to Improve Mucositis Management

Workshop – Additional Fees Apply

Saturday, June 25 2:00 PM – 5:30 PM EDT (including coffee break)

View the Detailed Scientific Program for more details

Emerging Toxicities Associated with Immune Checkpoint Inhibitors

Workshop – Additional Fees Apply

Saturday, June 25 2:00 PM – 5:30 PM EDT (including coffee break)

View the Detailed Scientific Program for more details

Study Group Business Meetings of Interest:

- Mucositis – Saturday, June 25 2022 7:30 AM – 8:30 AM EDT

Social Events

- Welcome Reception & Awards – Thursday, June 23 5:30 PM – 7:30 PM EDT
- New Member Breakfast (By Invitation Only) - Friday, June 23 7:30 AM – 8:30 AM EDT
- “A Roaring Presidential Reception” (By Invitation/Purchased Ticket Only) – Friday, June 24 7:15 PM – 11:00 PM EDT

Scientific Program

New Oral Care Study Group (OCSG) Chair

Dear members and friends,

I am sending this email on behalf of the ISOO Board, to formally announce that our new chair of the OCSG has been accepted by Sharon Elad. As Sharon requires no introduction, I think all I can say is how honored we are that you have considered to accept this position Sharon!



We would also like to thank Drs. Erin Watson and Cherry Estilo, who will be completing their terms as OCSG co-chairs in June 2022.

Thank you again Sharon for your acceptance of this role. We are really very excited to have you on board.

Sincerely,
Eduardo Fregnani, ISOO President

Meet a New ISOO Member: Dr. Noa Stempler

Hello ISOO members,

My name is Noa Stempler, and I'm grateful to be part of this global community.



I am married to Tzahi and a mother of two sweet boys. We live in Nes-Ziona, a city in the center of Israel. Tzahi is a physician by profession but a farmer at heart, and thanks to him we enjoy a little piece of nature in our urban life.

I am in my fourth and last year of the Oral Medicine Residency program at Sheba Medical Center, Israel. I am a graduate of The School of Dentistry <https://mascc.memberclicks.net/2022-program#al> Medicine, Hadassah, Jerusalem, in 2009, since then I worked in private clinic as general practitioner. I also graduated in business management and sociology in 2003.

Practicing oral medicine interests me, because it combines different disciplines. We treat a diverse population with a variety of oral medical issues and underlying conditions as part of Israel's largest medical center. For me, the most fulfilling and challenging aspect of our practice is the treatment of cancer patients and survivors, where we put effort into improving their basic oral functions and their quality of life.

Research is an integral part of our work, and we encounter so many ideas almost every day. I have the opportunity to be part of an EORTC study concerning the late toxicity and long term QoL in head and neck cancer survivors. Other projects in which I'm taking part of are oral cancer in cGvHD patients, metastases to the jaws and oral manifestation of oncologic medications.

I'm looking forward to the MASCC/ISOO 2022 meeting, see you then :)

OraRad Study Investigators Publish Several Important Findings

Congratulations to our ISOO members who recently published a number of clinically relevant findings from the landmark OraRad study. OraRad is a large multicenter prospective cohort study examining oral complications after radiation therapy (RT) for head and neck cancer. The study team enrolled 572 participants, who were examined prior to RT and then every 6 months until 2 years after RT. Some of the most notable findings include:

1. Despite comprehensive pre-RT dental management, 17.8% of study participants had a tooth loss within 2 years after RT (95% CI 14.3% to 21.3%). Risk factors for tooth loss within 2 years included fewer teeth at baseline, greater reduction in salivary flow, and non-compliance with oral hygiene measures.

<https://pubmed.ncbi.nlm.nih.gov/34879248/>

2. Radiation therapy for head and neck cancer led to a striking increase in gingival recession, in a dose-dependent manner. The mean distance from the cemento-enamel junction to the gingival margin decreased by an impressive 74% during the two-year study period. Greater gingival recession was associated with increased caries on the facial/buccal surfaces. These findings help explain the increased risk for cervical caries seen in this population.

<https://pubmed.ncbi.nlm.nih.gov/35304084/>

3. Exposed intraoral bone was diagnosed in 35 of the 572 participants (6.1%) in the 2 years after RT. Exposed bone occurred more often in the mandible (76% of episodes). The mean RT dose to the area of exposed bone was approximately 55 Gy. A diagnosis of osteoradionecrosis was confirmed in 18 participants (3.1%). Risk factors for exposed bone included pre-RT dental extractions, higher RT dose, and current tobacco use.

<https://pubmed.ncbi.nlm.nih.gov/34665873/>

4. Even with use of Intensity Modulated RT and modern planning techniques, stimulated whole salivary flow was greatly reduced at 6 months after RT, to 37% of pre-RT levels. This was followed by a partial recovery in salivary flow, to 59% of pre-RT levels at 18 months. Patient-reported changes in dry mouth, sticky saliva, swallowing, and mouth opening were significantly associated with measured changes in salivary flow.

<https://pubmed.ncbi.nlm.nih.gov/35231809/>

5. There was a modest increase in dental caries within the first two years after RT. The mean score for Decayed, Missing and Filled Surfaces (DMFS) was 47.6 at baseline (pre-RT), which increased to 51.9 at the 24-month visit. The increase in DMFS score was significantly smaller for patients compliant with daily fluoride use and oral hygiene, patients with dental insurance, and those with greater than a high school education.

<https://pubmed.ncbi.nlm.nih.gov/35403479/>

The OraRad study is funded by the US National Institute for Dental and Craniofacial Research (Program Officer Dr. Dena Fischer), through a grant (U01 DE022939) awarded to the study Principal Investigators Dr. Michael Brennan (Atrium Health) and Dr. Rajesh Lalla (Univ. of Connecticut Health). The other clinical site PIs are Dr. Nathaniel Treister (Brigham and Women's Hospital), Dr. Thomas Sollecito (Univ. of Pennsylvania), Dr. Brian Schmidt (New York Univ.), and Dr. Lauren Patton (Univ. of North Carolina at Chapel Hill). The study Data and Coordinating Center is located at the Univ. of Minnesota (PIs Dr. Erika Helgeson and Dr. James Hodges).

Fellowships

Do you want to advertise your Fellowship or other Job Opportunities in our next ISOO Newsletter? Please email jonnwu@bccancer.bc.ca.

All issues of the ISOO Newsletter are [available online](#).

Get Connected



This message has been sent to you because you are a member of ISOO.

[Contact ISOO](#)